This study represents an important step forward in gastric cancer study, because it proved the value of targeting VEGFR drugs, including VEGFR-Ab and VEGFR-TKI, on the basis of available evidence that supports the use of ramucirumab [43]. This evidence concerns the gene KDR and gastric cancer.